The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | EMN20: KRd versus Rd in non-frail, transplant-ineligible patients with NDMM
In this video, Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the results of the EMN20 trial (NCT04096066) which is evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus Rd in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
